We absolutely crushed it today. $SRPT - my largest single stock position. +33% today alone. Subscribe for my full portfolio, live trade alerts and access to 1V1 DM's. https://t.co/WAqWmc0193

Hope you listened and didn't get shaken out. $SRPT +29% today. https://t.co/8e0GoIwhiP

Hope you listened, $SRPT +22% today based on positive pipeline update. My largest single stock position. https://t.co/oa6cU3YMkn

Breaking: Phase 1/2 Preliminary Data Readout for $SRPT 's sirNA DM1 and FSHD Programs to be released tomorrow morning. This could be a big catalyst for the stock if positive results - huge TAM for sirNA pipeline. https://t.co/3uforkcmOI

$SRPT catching a bid. My largest single long stock position. https://t.co/foqEUBm2hh

$SRPT +3.1% $DND.TO +6.2% There will always be opportunities in single stocks. While the broader market continues its decline - $SPY down another -0.8%, and bonds continue sell off on rising yields from oil shock.

$SPY down -0.62% Meanwhile my three high conviction plays: $SRPT +2% $DND.TO +1.1% $TLT +0.1%

$SRPT News: Screening & enrollment underway in ENDEAVOR Cohort 8 for non-ambulatory Duchenne patients! Testing enhanced sirolimus regimen and ELEVIDYS to minimize liver toxicity risks in this harder-to-treat group. Why very bullish: - Non-ambulatory patients represent a major portion of the total DMD population (disease progression leads most there). -Success paves way for label expansion and significant TAM growth for Elevidys. - Addresses key safety concerns, unlocks unmet need in older patients. Strong long-term catalyst. Revenue Context: - 2025 ELEVIDYS net product revenue: $898.7 million (full year - already strong despite the June 2025 non-ambulatory pause and flu-season logistics issues; Q4 alone $110.4M). - 2026 total net product revenue guidance: $1.2 to 1.4 billion (model toward low end); - ELEVIDYS $500M+ floor reaffirmed (ambulatory-only for now). Post-expansion revenue potential: - Re-opening non-ambulatory could add $500M–$1B+ incremental annual run-rate over time (backlog of older patients and new diagnoses). - Pre-setback analyst models for broader label routinely targeted $2B–$5B+ peak (US + ex-US). Even conservative scenarios show meaningful uplift as majority of ambulatory patients remain untreated today. My price target for 2026 is $50 - my largest single stock position.

$TLT , $ZFL.TO . $SRPT, $DND.TO all going higher today while my shorts print too $OKLO $IONQ $RGTI $QBTS Subscribe for my complete portfolio.

$SRPT my largest single stock position. +5.5% today. This will continue to go higher given Friday's news of Prasad's departure from the FDA. https://t.co/LvCRdBVjED

I called it. Prasad out - $SRPT to the moon https://t.co/6zRPFXB1xE

$SRPT - don't sleep on it. My largest single stock. https://t.co/xG9Pbylb0F

$SRPT moving nicely- still my biggest single stock. This stock will double in 2026. https://t.co/nkXzr6HMH2

Rolling profits into $SRPT. It's coming. https://t.co/u5d53AEGP9

$SRPT: I just bought rolling my profits from DND into Sarepta. Very Bullish view just released from Jeffries (to add to Oppenheimer's $37 price target) just released - multiple near-term shots on goal for a rebound year. Jefferies / Andrew Tsai reiterates 𝐁𝐮𝐲 and maintains $30.00 price target (current ~$16 implies +87% upside. Analyst frames SRPT as a potential 2026 recovery story with multiple high-conviction catalysts: - New Elevidys launch initiative and expected sales rebound in H2’26 (80% of ambulatory DMD patients still untreated) - Q1’26 initial DM1/FSHD data readouts ($1B+ opportunity each) - More complete MAD data in H2’26 which could spark +25-50% stock move Expected FDA meeting in Q1’26 on next steps for two PMOs post-ESSENSE.

$SRPT's market cap is $1.7 Billion meanwhile their Revenue... When will @Roche get their act together and scoop them up at a steal! https://t.co/cNl19THj0L

Wells Fargo just put out a BUY rating on $SRPT of $38 dollars. https://t.co/6axXb0wxWv

My 3 highest convictions plays right now: - $TLT (Price target of $120 by the end of 2026) - $SRPT (Price target of $50 by the end of 2026) - $DND.TO / $DYNDF (buyout incoming - easy double)

Breaking: The FDA is now investigating internal complaints about Dr. Vinay Prasad,CBER director, with the help of an external investigator. $SRPT $MRNA $CRSP $EDIT $BEAM This is an extremely rare step. There is serious concerns about workplace issues at the agency! The move comes amid broader turmoil at the FDA, including criticism of Prasad’s leadership style and controversial decisions on drug and vaccine reviews - e.g. the recent Moderna’s flu shot or the non-ambulatory ban on Sarepta's Elevidys. If Prasad is pushed out, this will be extremely bullish names sensitive to regulatory tone, including: - $SRPT (Sarepta) - gene therapy pipeline - $MRNA (Moderna) - vaccine/therapeutic approvals - $CRSP (CRISPR Therapeutics) - gene editing assets - $EDIT (Editas Medicine) - FDA review path clarity - $BEAM (Beam Therapeutics) - precision editing programs Personally I think he will be gone in the next month - thoughts? https://t.co/ozEVcdKIz5

I know you can't compare quantum hype ( $RGTI ) vs real commercial biotech ( $SRPT ) sectors/stages...But this shows how ridiculous narrative & hype control valuations: - $RGTI: $6.12B mcap on $21M 2026 Revenue with a 290x P/S! Meanwhile - $SRPT: $1.80B mcap on $1.75B 2026 Revenue with a 1x P/S $SRPT is forecasted to do 83× more revenue… yet $RGTI trades at 3.4× higher market cap.

Oppenheimer reiterate Buy rating on $SRPT following their earnings release. Price Target of $37 dollars. Current price trading around $17 - this will double in 2026. I'm continuing to accumulate. https://t.co/eEOmTFF84u

Trade alert: just added to my $SRPT position.

BREAKING: $SRPT CEO IS RETIRING IN 2026! Huge positive for the stock - expect a big rally tomorrow!

Breaking: $SRPT earnings released: - Q4 total rev $442.9M beats consensus $390-410M (product $369.6M: ELEVIDYS $110.4M + PMO $259.2M). - Non-GAAP EPS -$3.58 misses est -$0.8 to -$1.2 (wider loss on ops/investments). Miss on EPS was due to messy one time hits - blame: $200M Arrowhead DM1 milestone + $165M+ inventory write-offs/reserves (excess ELEVIDYS/PMO after non-ambulatory pause). FY: rev $2.20B (+16% YoY), net product $1.86B. Cash $954M. Overall: Revenue beat plus strong cash plus Japan ELEVIDYS launch plus positive 3-yr EMBARK data plus siRNA pipeline progress. Guiding profitable & cash-flow positive in 2026. Clear path forward! Overall I like it even if market doesn't. https://t.co/OB9kImuakV

THE BIG DOG IS BACK @MartinShkreli streaming now below. @MartinShkreli please give the peepz an update on $ionq and $srpt earnings after the bell on stream.

Question from a subscriber on what I’m watching for in $SRPT ahead of tomorrow’s earnings: If even a couple of these catalysts land, I think we could see a strong 10–15% after-hours move. My price target remains $50 over the next 12 months. Here’s what matters: 1. Meaningful progression updates across the SiRNA pipeline 2. A guidance raise reflecting Japan revenue ramp from Elevidys 3. Clear commentary on non-ambulatory discussions with the U.S. Food and Drug Administration and a defined path forward 4. Timeline and detail on Elevidys resubmission to the European Medicines Agency 5. Updated patient uptake trends and safety data There are multiple shots on goal here - and expectations are still low. Call will be just after market close tomorrow - 4:30 EST - will be streamed here: https://t.co/tTTTVcVWfX

$SRPT looking strong ahead of earnings tomorrow +4% today and looking explosive. My largest single stock position. https://t.co/IxrHk6EsLF

$SRPT: Breaking As a reminder Roche holds ex-U.S. rights for Sarepta's core Elevidys drug. This is big for $SRPT (announced today): - Japan launch of Elevidys (via Roche's Chugai) triggers milestones/royalties (~¥305M/patient pricing) and meaningful expands market, validates the gene therapy and mitigates risks in U.S. competition. Would not be surprised if Roche bought out Sarepta at this valuation. This would be an easy 3 to 5x if buyout went through (i.e. 6B to 10B range). https://t.co/IoyfDSHWYM

$SRPT continues its climb higher. My largest single stock. Earnings Feb 25 - pay attention. https://t.co/z6AqTI85Vz

$SRPT keeps grinding higher. Steady accumulation over the past few sessions - even as the broader market pulls back. Very interesting price action ahead of earnings next week - don’t get shaken out. https://t.co/sLzYeyPysD

$SRPT - strong bounce-back today +3.5%. Earnings release next week (FEB 25th). I think we get a beat and raise on forecasts along with positive pipeline update. My largest single stock position. https://t.co/stAEuYekTJ

Surely Vinay Prasad has got to go! $MRNA $SRPT $NVO $CAPR https://t.co/prNAwP1TNg

$SRPT Elevidys has been listed on Japanese NHI drug price list of 30,500,000 JPY Elevidys has finally been listed at a drug price exceeding 300 million yen! Congratulations, Chugai & Sarepta.

If I made you money or saved you money - support the mission and subscribe to my my sub. It helps me out. $IONQ $RGTI $BTQ $OKLO $JOBY $SRPT $TLT I post my full portfolio, live trade alerts and answer DM's one on one. You also support the mission of bringing the truth to retail investors not just hype and a controlled narrative!

I keep accumulating more $SRPT at these prices. So much value, their valuation is trading under revenue multiple. Thank me by the end of 2026 when this rockets to $50

TRADE ALERT: I just added to my $SRPT position - my largest single stock position. $50 price target in 2026. https://t.co/OB9JZRZjIw

Trade Alert: I added more to my $SRPT position at market open. https://t.co/28fqQO35we

Trade Alert: Live trade alerts go in my sub - just added to my $SRPT position on this pull back.

Hope you listened. $SRPT up 15% https://t.co/KBxLWsflEL

Listening to the Q&A on the $SRPT data release today on their core gene therapy Elevidys. Even more bullish on the stock. I just added to my position, my largest single stock position - this stock will rip back to $50.

$SRPT Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients https://t.co/92kquksGmA

$SRPT keeps going higher in overnight markets just opened. +11.22%. Good sign ahead of data release in the morning at 8:30 EST. If results are positive this could rip +30% in a day. https://t.co/dxc4MloulE

Who is holding $SRPT through the data release Monday morning? $SRPT will present 3-year topline data from the Phase 3 EMBARK study of its Duchenne gene therapy ELEVIDYS on at 8:30 am ET Monday morning. If positive stock could rip 30%+ and continue march to $50. If negative, stock could easily drop 15 to 20% in a day.

Over the past 12 months, @adamfeuerstein’s X posts about Sarepta ( $SRPT ) show an unusually consistent and aggressive negative narrative - often echoing, amplifying, or previewing themes later used in STAT coverage. $SRPT $SLDB $RGNX $CRSP $EDIT $NTLA $BEAM $VRTX $REGN $BLUE $EXEL $ILMN $GILD $AMGN $PFE $MRNA $LLY $JNJ $AZN $NVO $IBB $XBI $CAPR Just a few examples, in his own words: 1. “Sarepta may not survive… the company is facing a severe cash flow and debt crisis…” (July 24, 2025) 2. “The company has never conducted a successful clinical trial… What is the acceptable death rate? There will be more Elevidys-related deaths…” (Aug 21, 2025) 3. “Sarepta’s dismal quarter marred by drug failures and a long list of excuses.” (Nov 4, 2025) 4. “The Worst Biopharma CEO of 2025… decisions with tragic consequences.” (Dec 17, 2025) (my personal favourite) These aren’t isolated reactions - they form a repeated thesis: failure, incompetence, opacity, and inevitable collapse. Now contrast that tone with the reality of Duchenne muscular dystrophy: - A fatal genetic disease that almost exclusively affects young boys - Progressive muscle loss starting in early childhood - Loss of ambulation in the early teens - Average life expectancy historically in the 20s - Families with no curative options, only hope for time Sarepta’s stated mission is to “transform the lives of patients with rare diseases.” For Duchenne families, that mission isn’t theoretical - it’s existential. That doesn’t mean safety questions shouldn’t be asked. They should. It doesn’t mean trials shouldn’t be scrutinized. They must be! But when coverage - across dozens of posts - and through his STAT news site repeatedly frames one company as reckless, deceptive, or doomed, while downplaying context, trade-offs, and the absence of alternatives, it’s fair to ask: Where does rigorous skepticism end - and personal framing begin? Readers deserve full context, families deserve seriousness and journalism works best when criticism informs - not when it feels prosecutorial!!

BREAKING: $SRPT o present 3-year topline data from the Phase 3 EMBARK study of its Duchenne gene therapy ELEVIDYS on Jan 26 - spotlighting long-term outcomes in ambulatory patients treated with the therapy. Data webcast scheduled for 8:30 am ET. STOCK UP NEARLY 10% after hours! https://t.co/iZUyuMryQF

$SRPT up another 3% today on Wedbush analyst price target raise. https://t.co/2BmcZLKZgP

MUST KNOW: The Real Deal on Investing If You're Not an Expert If you're not great at investing - or don't have the time or money to follow markets closely (like paying for a pro advisor) - here's the straight talk for everyday (retail) investors: 1. Prefer low risk? You'll likely get about 8% yearly returns in USD (e.g., safe index funds like those tracking the S&P 500). Just accept it, be patient, and let steady growth (compounding) work its magic - instead of chasing flashy hype. 2. Love high risk? You're an easy target for scams, Ponzi schemes, and fake "breakthroughs" like quantum tech stocks ( $IONQ, $RGTI). Mixing get-rich-quick dreams with no real knowledge? That's a recipe for total loss. Trust me, I've watched it happen over and over. 3. Got big wealth (high net-worth)? None of this applies- you can hire top advisors to open doors to exclusive deals and bigger potential gains (e.g. venture, private equity) But here's the game-changer: 1. Build real financial smarts (common-sense style), and your options explode! See clearly: You'll spot hidden gems (undervalued stocks like $META or $SRPT) in the chaos, match investments to your actual risk level, and dodge overhyped duds. 2. Wealthy folks focus smart: They don't try everything - they get super good at just 1-2 things they love (like bargain-hunting value stocks or smart sector picks, e.g., long-term bonds like $TLT right now). Then, they let pros (funds or managers) handle spreading out the rest. No wasting energy on too many bets - focused wins big, without the ego trips. 3. Smarts open doors: You'll tap into real networks and group deals for more capital - not just random Reddit or X buzz. That's how wealth really builds and lasts. 4. Patience is key: Don't jump around chasing every trend or feel the urge to trade constantly. Stick to your high-conviction ideas and let them play out over time - real winners need room to grow, not constant tinkering. On your path to wealth, make learning your top priority- numbers are simple tools, not scary monsters, and they're your secret weapon. Kick off with my top 5 classic reads (see below).

$IONQ cratering down nearly 6% today while the broader market is ripping. My longs are pushing higher e.g. $SRPT, $INTC, $BHVN, $CMG, bonds are back up today $TLT, and shorts are printing e.g. $IONQ , $RGTI, $QBTS. Subscribe for my full portfolio and trade alerts. https://t.co/nfNZJkOZsx

$SRPT continues it's rebound. Do not get shaken out of this one - $50 dollars is incoming in 2026. https://t.co/OycAr6u58F

I hope you didn’t get washed out, bouncing back nicely. $SRPT will see $50 this year. https://t.co/rM3hILpQ2S